Under the expanded agreement, Pfizer will use four components of Inpharmatica's PharmaCarta technology platform. These components are in addition to Pfizer's current subscription to Biopendium, which the company first licensed five years ago.
Pfizer will gain access to Inpharmatica's StarLite database of curated medicinal chemistry information; to its DrugStore database of all known drugs, linked with their targets; and to the Admensa ADME prediction platform.
Inpharmatica will also use its proprietary PharmaCarta technology for a druggability assessment study.
Financial terms of the new agreement were not disclosed.